Crescent Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CBIO research report →
About the company
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors.
- CEO
- Joshua T. Brumm
- IPO
- 2014
- Employees
- 41
- HQ
- Waltham, MA, US
Price Chart
- Market Cap
- $471.20M
- P/E
- -3.21
- P/S
- 39.65
- P/B
- 2.83
- EV/EBITDA
- -1.79
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -1372.85%
- Net Margin
- -1363.94%
- ROE
- -100.86%
- ROIC
- -88.00%
- Revenue
- $10.84M · 0.00%
- Net Income
- $-153,942,000 · -217.25%
- EPS
- $-14.78 · -955.71%
- Op Income
- $-152,632,000
- FCF YoY
- -132.90%
- 52W High
- $27.41
- 52W Low
- $8.72
- 50D MA
- $19.34
- 200D MA
- $14.50
- Beta
- 1.19
- Avg Volume
- 316.50K
Get TickerSpark's AI analysis on CBIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 22, 26 | Lynch Ryan | sell | 465 |
| Jun 22, 26 | Pinkas Jan | sell | 1,288 |
| Jun 22, 26 | Scalzo Richard William | sell | 1,112 |
| Jun 22, 26 | Bispham Barbara Harlin | sell | 1,218 |
| Jun 22, 26 | Im Ellie Eunkyung | sell | 1,219 |
| Jun 22, 26 | McNeill Jonathan | sell | 20,549 |
| Jun 22, 26 | Brumm Joshua T | sell | 42,305 |
| Jun 2, 26 | Violin Jonathan | other | 11,050 |
| Jun 2, 26 | Lubner David Charles | other | 11,050 |
| Jun 2, 26 | Balcom Alexandra | other | 11,050 |
Our CBIO coverage
Recent articles, reports, and earnings notes.
No research on CBIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CBIO report →Similar companies
Peers in the same neighborhood.